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            ABSTRACT 
 
Lactate dehydrogenase (LDH) is essential for continuous glycolysis necessary for 
accelerated tumor growth. The aim of this study was to reconsider if assay of total tissue 
activity of this enzyme could be useful as marker for endometrial carcinoma. 
Activity of LDH was measured spectrophotometrically in homogenate supernatants of 
uterine tissue samples of 40 patients (10 normal endometria, 27 normal myometria, and 33 
endometrial carcinoma), including 30 matched pairs. Data obtained were analyzed in 
relation to clinical and histopathological findings, and compared with our previously 
published results on the tissue levels of the same enzyme in ovarian cancer and on the 
proteolytic activity of dipeptidyl peptidase III (DPP III) in endometrial carcinoma 
(suggested biochemical indicator of this malignancy).  
Significantly increased (1.8 - 3.0 times, P<1x10-4) LDH activity was observed in 
endometrial carcinoma samples, if compared with normal uterine tissues. This rise was not 
related to the clinico-pathological findings, however. In contrast to previous results on 
LDH in ovarian carcinomas, a significant rise in LDH activity was found already in grade 
1 endometrial carcinoma. Using the cutoff value of 1.06 U/mg, diagnostic sensitivity of 
82%, specificity of 100% and accuracy of 91% for total tissue LDH assay have been 
calculated. A correlation of tissue’s LDH and DPP III activities was found, and their 
combined assay for endometrial carcinoma showed increased diagnostic sensitivity (94 %) 
and accuracy (96 %). 
 
 
 
INTRODUCTION 
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Cancer of the corpus uteri is the eighth most common malignant neoplasm in 
women worldwide, and endometrial cancer constitutes about 95% of all malignant lesions 
of uterine cavity(1). The prevailing form of endometrial cancer is endometrial carcinoma 
(EC), tumor originating from the glandular epithelium of uterine endometrium. 
Endometrial carcinoma arises through a series of precursor lesions, which are thought to 
develop and be promoted in response to unopposed and prolonged stimulation by estrogen. 
On the other hand, some types of endometrial carcinoma are estrogen-independent(2). 
Endometrial carcinoma is usually postmenopausal disease with peak incidence between 
age 50 and 60. Prognosis of endometrial carcinoma is fairly good, since overall 5-year 
survival rate is 83% and for the early stage of the disease, about 90%(1). This is mainly due 
to early diagnosis indicated by abnormal bleeding and based on mandatory endometrial 
biopsy which is strengthened by transvaginal ultrasonography, hysterescopy, vaginal and 
endometrial cytology and biochemical clinical tests. One among these lasts, assay of 
lactate dehydrogenase (LDH), is still under clinical evaluation in gynecological oncology. 
    Lactate dehydrogenase, (EC: (S)-lactate:NAD+ oxidoreductase, 1.1.1.27) is one of 
the major glycolytic enzymes that catalyzes the last step of glycolysis, conversion of 
pyruvate to lactate. It is a tetrameric protein composed of two immunologically distinct 
subunits, “A” or “M” (muscle) and “B” or “H” (heart) type, which combine to form five 
isoenzymes(3).  
LDH is ubiquitous cytosolic enzyme present in all tissues, wherein shows origin- 
and tissue-specific isoenzymatic pattern(4). Routine serum measurement of this enzyme is 
of clinical use in the diagnosis and monitoring of certain diseases including cancer, but is 
of low diagnostic value for gynecological malignancy(5) . In response to the need for more 
specific diagnostic and prognostic tools, attempts have been made also to measure LDH in 
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other body fluids(6,7), cavity washings(8), and uterine tissues(9–14). Since data for these last 
are still scarce and our recently published results on ovarian carcinoma(15) indicated  
correlation of total tissue LDH activity with histological epithelial tumor grade, we wanted 
to extend our research to uterine tissue. Therefore, we assayed total LDH activity in the 
extracts of normal and malignant endometrial tissue, and correlated it with 
histopathological and clinical data. In addition, the diagnostic value of the total tissue LDH 
for endometrial carcinoma was calculated and compared to that of proteolytic enzyme 
dipeptidyl peptidase (DPP III) which was previously shown by us to be a biochemical 
indicator for endometrial and ovarian cancer(16, 17).             
           
MATERIALS  AND  METHODS 
 
Patients and Samples.  This study covered 40 patients undergoing surgical treatment at 
the Department of Obstetrics and Gynecology, School of Medicine, University of Zagreb, 
Croatia. The mean age of patients was 60.6 ± 1.7 (mean ± SEM) years. The consecutive 
specimens of uterine tissues obtained at surgery or biopsy comprised 10 samples of normal 
uterine endometrium (NE), 33 samples of endometrial carcinoma (EC), and 27 samples of 
normal uterine myometrium (NM). Among them were 30 matched pairs (endometrial 
carcinoma/normal uterine tissue) originating from the same patient, and having normal 
uterine endometrium (n = 5, “true” pairs) or normal uterine myometrium (n = 25, “virtual” 
pairs) as endometrial carcinoma’s counterpart. Patients were untreated for endometrial 
carcinoma before the sampling.  
Histopathologic classification of endometrial carcinoma samples was based on the 
International Federation of Gynecologists and Obstetricians (FIGO) staging system 
Additional histopathological characteristics included determination of the degree of 
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leukocyte infiltration. Clinical informations were obtained after completion of biochemical 
assays. The protocol was approved by the Ethics of the Research Committee at the School 
of Medicine, University of Zagreb. 
Tissue Sampling and Processing. Samples of uterine tissue were frozen within 10 min in 
liquid nitrogen and kept at -196 C until use. For biochemical assays, tissues were minced, 
suspended in a buffer (50 mM Tris.HCl, 250 mM sucrose, 134 mM KCl, pH 7.6) and 
homogenized on ice (Ultra-Turrax T 25 homogenizer, Janke&Kunkel, Ika-Labortechnik, 
Germany) for three 5 s bursts. Supernatants obtained after centrifugation (4 C, 15 min, 
15,000 x g) were used for analysis. 
Biochemical assays. Total tissue LDH activity was determined by following initial rate of 
pyruvate reduction to lactate, using slightly modified procedure(18). Assay mixture of 1 mL 
was buffered by 100 mM potassium phosphate pH 7.0, and contained finally 0.096 mM 
pyruvate and 0.060 mM NADH. Reaction was started by the addition of enzyme sample 
(up to 20 L supernatant of tissue homogenate), and followed spectrophotometrically at 
room temperature  (25º C) for 3 min by measuring decrease in absorbance of NADH at 340 
nm. Initial velocity was calculated using the linear regression method. The specific activity 
of LDH was expressed in units per mg (U/mg) of the sample protein. One unit of enzyme 
activity was defined as the amount of enzyme which transforms (reduces pyruvate or 
oxidizes NADH) one mole of substrate in one minute at 25 C and pH 7.0. 
   Specific activitiy of the DPP III was determined as described elsewhere(16). 
Protein concentrations were measured by the protein-dye binding assay(19). 
Statistical Analysis.  The results were analyzed statistically using the STATISTICA 
(StatSoft Inc., 1984–1995, Version 5.0) software, by evaluating groups consisting of at 
least five pieces of data. Mainly normal or normalized distribution of the data prompted us 
to apply methods of parametric statistics for their evaluation – (in)dependent t-tests for the 
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analysis of differences between the groups, and simple linear regression analysis, for the 
correlations among parameters assayed, have been used. In a few other cases however, 
distribution-free methods were employed – differences between groups of independent 
samples were analyzed by Mann-Whitney U-test, those between dependent (paired) 
samples using Wilcoxon’s paired samples test, and correlations among parameters assayed, 
by Spearman “rho” method. Two tailed probability values of less than 0.05 were 
considered to be significant. Calculation of diagnostic parameters for LDH- and DPP III-
assay was performed according to Schneider et al.(8), using cut-off values of enzyme 
activities as mean + 2 SD of the control group (normal uterine tissue consisting of 
endometrium plus myometrium) sample. 
 
RESULTS 
 
   Figure 1, Table1 and Table 2, present the results of total LDH activity 
determination in samples of normal uterine tissues and endometrial carcinoma. These data 
show that normal uterine myometrium had the lowest LDH enzymatic level (mean = 0.544 
U/mg, n = 27) which was about 30% lower than that found in normal uterine endometrium 
(mean = 0.808 U/mg, n = 10).  
    When all endometrial carcinoma samples have been compared with all normal 
uterine tissues, considerably higher levels (1.8–fold to 3-fold) of LDH activity (mean = 
1.525 U/mg, n = 33) have been observed in malignant than in normal uterine tissue (Figure 
1, Table 1). Similar values were also obtained when matched pairs of endometrial 
carcinoma and their normal counterpart tissue were compared (Table 2). There was no 
overlapping in total tissue LDH activity based on 95% confidence intervals (Table 1); thus 
the enzyme level was clearly distinguishable in each type of uterine tissue, and 
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significantly higher in the malignant one. Total LDH activity of endometrial carcinoma 
tissues apparently did not depend on the age of patients and was not related to the clinical 
stage, tumor grade, histological type of tumor or presence of tissue’s inflammation 
 (Table 1).   
In order to further examine diagnostic utility of total tissue LDH assay, we 
correlated activity  of this enzyme in the normal uterine tissues and endometrial carcinoma 
with levels  of DPP III determined earlier by us(16) (Table 3). Moderate (Pearson’s “r” ~ 
0.5) but significant association of LDH activity with DPP III  (P = 1x10-3) activity was 
found. For both of these assays cutoff values have been determined, and diagnostic 
parameters for separate and combined tests have been calculated (Table 4). Both assays 
showed similar specificity, positive predictive value and diagnostic accuracy, but DPP III 
assay seems to be superior to the LDH test concerning sensitivity and negative predictive 
value. Combined results of the assay of these two enzymes improved diagnostic 
parameters of LDH measurement alone, resulting in at least 96% reliability to discriminate 
endometrial carcinoma from normal uterine tissue.   
             
DISCUSSION 
 
   LDH is a ubiquitous cytoplasmic enzyme, and its appearance in body fluids is 
recognized as a pathological manifestation that can be used as a measure of cell or tissue 
injury. The determination of serum LDH, routinely used for diagnostic purposes for at least 
thirty years, was established as relevant in the diagnosis of myocardial infarction (late 
detection), hemolytic anemia, ovarian dysgerminoma and testicular germ cell tumor(20).  
Being necessary to enable continuous glycolysis for accelerated growth rate of 
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 malignant tissue, LDH has been subject of many investigations in tumor metabolism, and 
its clinical use as a possible tumor marker has been suggested. Increased total serum LDH 
activity and isoenzymatic “shift” toward “M” isoforms are reported for most of  
malignancies(21, 22).  Assay of LDH activity has been evaluated and in the diagnosis and 
monitoring of gynecological malignancies, contributed mostly by serum data and much 
less by other body fluids or tissue extracts. Increased total LDH activities have been 
reported for sera of the patients with ovarian(23) or cervical(24) cancer, and some tumors of 
uterine cavity(25).  Similar increase has been observed also for other body fluids and cavity 
washings of patients with gynecological malignancies – vaginal(7), uterine(6), and peritoneal 
fluid(8). With exception for ovarian dysgerminoma where increased levels of total serum 
LDH activity and its “H” isoforms have been well documented and accepted as useful in 
the managing of this disease(20), relevant diagnostic utility of LDH assay is not firmly 
established however, since observed changes are not enough sensitive and specific. All that 
is mainly due to different rates of clearing of LDH isoenzymes from the circulation(21), 
which consequently does not reflect true tissue enzyme activity. 
   Normal uterine tissue, cyclically influenced by sex hormones, differs in LDH 
level during menstrual cycle. Total LDH activity of normal uterine myometrium remains 
stable and is altered only by prolonged hormonal stimulation in pregnancy or post-
menopause and in the malignancy(26). On the contrary, total LDH activity of normal uterine 
endometrium gradually increases in almost linear fashion over the entire period of 
menstrual cycle(27), being lowest in early proliferative phase and highest in the late 
secretory phase(28). 
   Our results of measurement of total LDH activity in matched normal and 
malignant uterine tissues corroborate that neoplastic transformation of human endometrial 
tissue significantly increases activity of this important glycolytic enzyme. Endometrial 
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hyperplasia, which is considered as premalignant neoplasm(1), is characterized by 2-4 fold 
higher total tissue LDH level than that found in normal secretory endometrium(11). Even 
higher activities of this enzyme occasionally have been reported for limited number of 
endometrial carcinoma samples studied up to now - the four to eight fold rise has been 
observed in (totally) 17 endometrial carcinomas studied previously(9, 12, 14), and these 
findings were confirmed later(10, 11, 13) on additional several tenths of similar samples. This 
rise was proposed to represent an adaptation mechanism of energy supply and glycolysis to 
an increased demand for energy at a time when the normal capacity of oxygen consuming 
pathways becomes inadequate to satisfy the needs of proliferating malignant cells(10).  
To improve the knowledge on this tumor biology and biochemical diagnosis of 
 endometrial carcinoma, few other molecular markers are under study. Recent findings 
suggest possible use of some enzymes among which are glutathione S-transferase(29) which 
is involved in detoxification system, and proteases that participate in the degradation of the 
basement membrane and digestion of extracellular matrix in the course of invasion and 
metastasis. These last comprise collagenase(1) and cathepsin D(30) which were found to be 
elevated not only in malignant endometrial tissue but even in the hyperplastic(1) one, when 
these have been compared with normal or benign tissues(1, 30).  The increased level of 
another proteolytic enzyme, dipeptidyl peptidase III (DPP III) has been reported in 
endometrial carcinomatous tissue, but its role in malignant growth is not elucidated(16).  
    Increased glycolysis of the malignant tissue with the pronounced role of LDH 
together with the convenience of its measurement, makes this enzyme still current in the 
evaluation as a tumor marker in gynecological malignancy. In spite of that, diagnostic 
utility of LDH assay has not been (except for ovarian dysgerminoma) yet firmly 
established.  Therefore, we intended to contribute to these attempts by measuring total 
LDH enzymatic activity in homogenates of normal uterine tissues and endometrial 
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carcinoma, and correlating obtained data with routine clinical and histopathological 
findings and with tissue levels of DPP III, a suggested marker of endometrial carcinoma. 
Due to marked variability within human normal and neoplastic tissues which requires 
evaluation of paired specimens(31), we also analyzed separately 30 “matched pairs” in 
which malignant tissue and normal counterpart originated from the same patient. 
Determination of LDH by continuously monitoring consumption of NADH while pyruvate 
is converted to lactate is generally accepted by most of the European Societies for Clinical 
Chemistry(21) and was used in this study. Our results on assay of total LDH enzymatic 
activity in uterine tissues are consistent with earlier findings, yet with a few distinctions. 
Firstly, similarly to the findings of others, we observed significant increase in total 
tissue LDH activity when normal endometrium underwent malignant transformation to 
endometrial carcinoma. This elevation was however, far from some extreme values 
reported earlier(9-11, 14), and the difference could be probably result of the analytical and/or 
sampling methods applied. Secondly, thorough analysis of the obtained data showed no 
correlations with clinico-pathological findings, irrespectively of which endometrial 
carcinoma samples (paired or unpaired) were examined. This indicated that total tissue 
LDH assay may not be of prognostic value for endometrial carcinoma. High values of its 
diagnostic parameters (Table 4) suggest however, that this assay could be useful in the 
diagnosis of endometrial carcinoma. 
In precedent study (15) we found that grade 1 ovarian carcinoma, contrary to the 
G2 and G3 ovarian tumors, did not differ in total tissue LDH activity from normal ovarian 
tissue. In the present study, significantly enhanced total tissue LDH activity was measured 
in endometrial carcinoma samples of G1 and G2 grade, and no difference was observed 
between these two subgroups. Our results on well-differentiated endometrial carcinomas 
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point to the complexity and the difference in regulation of this glycolytic enzyme in 
malignant gynecological tissues.  
No single marker has proved sufficient to meet the full requirements of clinical  
application, and therefore many workers have reported that a combination of more than 
one marker would prove more effective than any single assay(24). In an attempt to establish 
such a tissue-based biochemical index for the diagnosis of endometrial carcinoma, we 
compared the levels of LDH and DPP III, two cytosolic enzymes, and found a significant 
correlation of LDH with DPP III in normal as well as in transformed uterine tissues (Table 
3). Further attempts have been focused on the comparison of diagnostic value of LDH and 
DPP III assays (Table 4). Obtained results imply that the first one is somewhat more 
specific and the second one, more sensitive; thus, a biochemical index consisting of LDH 
and DPP III assays showed diagnostic reliability of at least 96% to detect endometrial 
carcinoma. 
   The data presented in this study establish the cutoff value between LDH activity 
in normal and malignant endometrial tissue and show high diagnostic value of this assay in 
endometrial carcinoma, very close to those of a new tumor marker, DPP III. Therefore, 
total tissue LDH activity measured by simple, fast and inexpensive assay which showed 
high values of diagnostic parameters (sensitivity of 82%, specificity 100% and accuracy of 
91%) might be an additional marker for endometrial carcinoma. 
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Table 1.   
Total tissue LDH activity in normal uterine tissue and in primary endometrial carcinomas: distribution 
according to the clinical and histopathological findings 
                  
                   Total tissue LDH (U/mg protein) 
 Findings           n  _________________________________________________ 
               Mean    SD   Median     95% Confid. Int. 
      
Normal uterine tissue:    37    0.616   0.222   0.580    0.542 – 0.690 
  endometrium:     10    0.808   0.145   0.800    0.704 – 0.912 
  myometrium:     27    0.544   0.203   0.480    0.464 – 0.625 
 
Endometrial carcinoma:   33    1.525   0.633   1.460    1.300 – 1.749 
 - Clinical stage: 
       Ia            4          N/Aa 
   Ib        13    1.710   0.694   1.500    1.290 – 2.130 
   Ic        16    1.467   0.577   1.480    1.159 – 1.775 
- Tumor grade: 
G1       16    1.584   0.727   1.425    1.196 – 1.971 
G2       15    1.478   0.544   1.500    1.177 – 1-779 
G3         2          N/Aa 
- Carcinoma type: 
  Endometrioid    23    1.441   0.508   1.600    1.221 – 1.661 
  Mixed          8    1.694   0.967   1.810    0.885 – 2.502 
  Othersb          2          N/Aa 
- Inflammation: 
  Present      16    1.680   0.584   1.680    1.369 – 1.991 
  Absent      17    1.379   0.660   1.240    1.040 – 1.718 
- Age of patients: 
    50 years         5    1.356   0.411   1.250    0.845 – 1.867 
    50 years     28    1.555   0.666   1.480    1.297 – 1.813 
        
a  N/A, numbers too low for statistical analysis 
b  Clear cell carcinoma 1, undifferentiated carcinoma 1 
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Table 2                           
The comparison of total tissue LDH activity in malignant versus normal uterine tissues 
  
        Sample                        (n1/n2)                    Ratioa            Pb 
  
I. Endometrial carcinoma versus : 
   - Normal endometrium    33/10     1.825      0.000148** 
   - Normal myometrium   33/27     3.042           < 10-6* 
- Normal endometrium plus                       
   normal myometrium    33/37     2.517      < 10-6** 
 II. Pairedc samples: 
   - “True” pairs       5       2.128      < 10-6* 
    - “Virtual” pairs        25       2.775      < 10-6*    
     - “All pairs”          30       2.626       10-6* 
 
a Ratio of mean or median values of LDH activity 
b Calculated by “t-test” ( * ) or by “U-test” ( **  ) 
c Endometrial carcinoma versus normal tissue sampled from the same patient, where  counterpart is 
normal endometrium (“True” pairs), normal myometrium (“Virtual” pairs), or normal endometrium 
plus normal myometrium (“All” pairs) 
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Table 3                               
Correlationa  of total tissue LDH activity with activity of tissue dipeptidyl peptidase III  (DPP III)b  
 
                      DPP III        
Uterine tissue                          
                                                                          n       r         P 
 
Normal endometrium and myometrium   37      0.543     0.001      
Endometrial carcinoma         33      0.546     0.001      
   
a Pearson’s product-moment correlation, at significance level of 0.05 
b Calculated from the published data(16) 
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Table 4 
Diagnostic value of the total tissue LDH and tissue DPP III assays for detecting  
endometrial carcinoma 
 
Positive   Negative Diagnostic 
Assay  Cutoff valuea    Sensitivity Specificity  predictive  predictive accuracy 
           (%)   (%)  value (%)  value (%)  (%) 
 
LDH     1.06  U/mg   81.8   100   100    86.0    91.4 
 
DPP III   20.60 mU/mgb  90.9     97.3     96.8    92.3     94.3 
 
LDH + DPP III    -     93.9      97.3     96.9    94.7      95.7 
 
a Calculated on the basis of “all normals” (normal endometrium plus normal 
   myometrium) sample, as described under “Material and Methods” 
b Calculated from the published data(16) 
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Legend   for   Figure 1 
 
Fig. 1    Total LDH levels in normal and malignant uterine tissue. NE = Normal endometrium ( n = 10 ), 
NM = Normal myometrium ( n = 27 ),  CAE = Endometrial carcinoma ( n = 33 ). Enzyme  
activity was measured as described under “Materials and methods”. 
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